AR045203A1 - Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa - Google Patents

Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa

Info

Publication number
AR045203A1
AR045203A1 ARP040102760A ARP040102760A AR045203A1 AR 045203 A1 AR045203 A1 AR 045203A1 AR P040102760 A ARP040102760 A AR P040102760A AR P040102760 A ARP040102760 A AR P040102760A AR 045203 A1 AR045203 A1 AR 045203A1
Authority
AR
Argentina
Prior art keywords
inhibitors
coa
cholesteril
protein
ester
Prior art date
Application number
ARP040102760A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR045203A1 publication Critical patent/AR045203A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificación que comprende un inhibidor de la proteína de transferencia de colesteril éster como por ejemplo torcetrapib, entre otras, en una forma de solubilidad mejorada y un inhibidor de la HMG-CoA reductasa, donde la forma de dosificación proporciona la liberación inmediata del inhibidor de la HMG-CoA reductasa como por ejemplo atorvastatín, entre otros, y la liberación controlada del inhibidor de la proteína de transferencia de colesteril éster.
ARP040102760A 2003-08-04 2004-08-03 Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa AR045203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49240703P 2003-08-04 2003-08-04

Publications (1)

Publication Number Publication Date
AR045203A1 true AR045203A1 (es) 2005-10-19

Family

ID=34115617

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102760A AR045203A1 (es) 2003-08-04 2004-08-03 Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa

Country Status (16)

Country Link
US (1) US20050038007A1 (es)
EP (1) EP1653926A1 (es)
JP (1) JP2007501217A (es)
KR (1) KR20060033033A (es)
CN (2) CN1863511A (es)
AR (1) AR045203A1 (es)
AU (1) AU2004261058A1 (es)
BR (1) BRPI0413363A (es)
CA (1) CA2534371A1 (es)
IL (1) IL172875A0 (es)
MX (1) MXPA06001506A (es)
NO (1) NO20061072L (es)
RU (1) RU2006102981A (es)
TW (1) TW200517145A (es)
WO (1) WO2005011634A1 (es)
ZA (2) ZA200600179B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005041869A2 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US20080145427A1 (en) * 2005-02-03 2008-06-19 Alfred Berchielli Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN1331476C (zh) * 2005-07-05 2007-08-15 凌沛学 一种辅酶a舌下含片及其制备方法
WO2007067593A2 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Self-emulsifyng formulations of cetp inhibitors
KR100742571B1 (ko) * 2006-03-02 2007-07-25 충남대학교산학협력단 초임계유체 공정을 이용한 무정형 아토르바스타틴 칼슘염및 그 제조방법
EP2007346A1 (en) * 2006-05-08 2008-12-31 McNeil-PPC, Inc. Osmotic dosage form
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
KR100885029B1 (ko) * 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2008115529A1 (en) * 2007-03-20 2008-09-25 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids and cetp inhibitors
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
TW201016761A (en) * 2008-10-30 2010-05-01 Univ Nat Taiwan Microporous film and preparation and use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
MX2011013080A (es) 2009-06-16 2012-01-20 Pfizer Formas de dosis de apixaban.
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo METHODS OF MAKING OPTICALLY PURE BETA-LACTONES FROM ALDEHYDES AND COMPOSITIONS OBTAINED THEREFROM
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
WO2011100324A1 (en) 2010-02-09 2011-08-18 Ironwood Pharmaceuticals Inc. Cannabinoid receptor agonists
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
BR112012033341B1 (pt) 2010-06-30 2022-08-23 Cyclerion Therapeutics, Inc Estimulantes de sgc
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN103037946B (zh) * 2010-07-29 2015-07-22 田边工业株式会社 减压喷雾干燥方法及减压喷雾干燥装置
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
CN105833283A (zh) * 2010-11-04 2016-08-10 霍夫曼-拉罗奇有限公司 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
US20150080381A1 (en) 2012-04-12 2015-03-19 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
WO2013164257A1 (en) * 2012-04-30 2013-11-07 F. Hoffmann-La Roche Ag New formulation
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN104918608A (zh) * 2012-11-19 2015-09-16 雷迪博士实验室有限公司 Cetp抑制剂的药物组合物
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN105007899A (zh) * 2012-12-20 2015-10-28 卡希夫制药有限责任公司 用于提高生物利用度的口腔崩解片制剂
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
LT2970243T (lt) 2013-03-15 2020-03-10 Cyclerion Therapeutics, Inc. Sgc stimuliatoriai
EP3092231B1 (en) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20150190346A1 (en) * 2014-01-09 2015-07-09 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
US10300059B2 (en) * 2014-08-28 2019-05-28 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP7050759B2 (ja) 2016-09-02 2022-04-08 サイクレリオン・セラピューティクス，インコーポレーテッド 縮合二環式ｓｇｃ刺激剤
US11690828B2 (en) 2016-11-08 2023-07-04 Cyclerion Therapeutics, Inc. Treatment of CNS diseases with sGC stimulators
EP3538520A2 (en) 2016-11-08 2019-09-18 Cyclerion Therapeutics, Inc. Sgc stimulators
CN107019927A (zh) * 2017-04-18 2017-08-08 成都绿林科技有限公司 用于药品快速干燥的干燥机
CN109663373A (zh) * 2018-12-26 2019-04-23 无锡市林洲干燥设备有限公司 甲维盐闭式循环喷雾干燥系统
CN110773079B (zh) * 2019-11-18 2022-03-01 江苏博迁新材料股份有限公司 一种超声喷雾法制备超细粉球的方法
CN115724771A (zh) * 2021-08-30 2023-03-03 中国科学院过程工程研究所 一种用于制备n，n’-二苯基脲的装置系统及制备n，n’-二苯基脲的工艺

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10325A (en) * 1853-12-20 Improvement in manure crushers and sowers
US35125A (en) * 1862-04-29 Improvement in spring-balances
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
PT828495E (pt) * 1995-06-01 2003-01-31 Searle & Co Dispersoes solidas estabilizadas de misoprostol
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
NZ520176A (en) * 1997-07-31 2005-02-25 Kos Life Sciences Inc Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AU2001270937A1 (en) * 2000-08-15 2002-02-25 Pfizer Products Inc. Therapeutic combination
JP2004534822A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 低溶解度および／または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物
ATE444060T1 (de) * 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren

Also Published As

Publication number Publication date
RU2006102981A (ru) 2007-09-20
CA2534371A1 (en) 2005-02-10
CN1863511A (zh) 2006-11-15
TW200517145A (en) 2005-06-01
JP2007501217A (ja) 2007-01-25
MXPA06001506A (es) 2006-05-15
NO20061072L (no) 2006-05-04
US20050038007A1 (en) 2005-02-17
ZA200600179B (en) 2007-02-28
IL172875A0 (en) 2006-06-11
AU2004261058A1 (en) 2005-02-10
WO2005011634A1 (en) 2005-02-10
ZA200600853B (en) 2007-04-25
KR20060033033A (ko) 2006-04-18
EP1653926A1 (en) 2006-05-10
BRPI0413363A (pt) 2006-10-10
CN1870978A (zh) 2006-11-29

Similar Documents

Publication Publication Date Title
AR045203A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa
AR052104A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa
GT200300023A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
DOP2019000185A (es) Una formulación sólida de dosificación farmacéutica
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
NO20081636L (no) FAP - inhibitorer
CR20120244A (es) Inhibidores de la tirosina quinasa de bruton
HN2003000227A (es) Inhibidores de quinasas
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ATE471324T1 (de) Triazolophthalazine
MX2008001597A (es) Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
UY28134A1 (es) Formas de dosificación que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa- reductasa
BRPI0509926A (pt) imidazóis
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
EA201070292A1 (ru) Способ активирования регуляторных т-клеток
ECSP045466A (es) Inhibidores de la peptido-desformilasa
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
DK1713438T3 (da) Medicinsk sæbe
EA201070257A1 (ru) Ароматизированная терапевтическая композиция на основе глины
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
PA8795401A1 (es) Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina
NO20044186L (no) Peptid-deformylaseinhibitorer
DE60232650D1 (de) Peptiddeformylaseinhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal